EGCG suppresses IDO-mediated tumor immune escape by blocking the IFN-γ-triggered JAK-PKC-δ-STAT1 signaling pathway, which is considered to be a potential immunological and targeted therapeutic agent. This evidence concerns the gene STAT1 and neoplasm.